Pheochromocytoma and paraganglioma
HPH Neumann, WF Young Jr… - New England journal of …, 2019 - Mass Medical Soc
Pheochromocytoma and Paraganglioma Pheochromocytoma and paraganglioma are
related tumors that differ mainly in location; pheochromocytomas are adrenal, and …
related tumors that differ mainly in location; pheochromocytomas are adrenal, and …
[HTML][HTML] The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
S Ghalehbandi, J Yuzugulen, MZI Pranjol… - European Journal of …, 2023 - Elsevier
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …
between health and disease. In spite of its central role in physiological homeostasis, it …
[HTML][HTML] Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
J Hadoux, R Elisei, MS Brose, AO Hoff… - … England Journal of …, 2023 - Mass Medical Soc
Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
advanced RET-mutant medullary thyroid cancer in a phase 1–2 trial, but its efficacy as …
[HTML][HTML] Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
M Chevallier, M Borgeaud, A Addeo… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …
leading cause of cancer related-death worldwide. It is now recognized that a significant …
Precision therapy for RET-altered cancers with RET inhibitors
Rearranged during transfection (RET) is involved in the physiological development of some
organ systems. Activating RET alterations via either gene fusions or point mutations are …
organ systems. Activating RET alterations via either gene fusions or point mutations are …
[HTML][HTML] Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma
A WellsSamuel Jr, L AsaSylvia, B EvansDouglas… - Thyroid, 2015 - liebertpub.com
Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
JWM Lenders, QY Duh, G Eisenhofer… - The Journal of …, 2014 - academic.oup.com
Objective: The aim was to formulate clinical practice guidelines for pheochromocytoma and
paraganglioma (PPGL). Participants: The Task Force included a chair selected by the …
paraganglioma (PPGL). Participants: The Task Force included a chair selected by the …
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
[PDF][PDF] Guidelines for the management of thyroid cancer.
P Perros, K Boelaert, S Colley, C Evans… - Clinical …, 2014 - rouxgroup.org.uk
Guidelines for the management of thyroid cancer Page 1 CLINICAL ENDOCRINOLOGY
VOLUME 81 SUPPLEMENT 1 JULY 2014 THE CLINICAL JOURNAL OF THE SOCIETY FOR …
VOLUME 81 SUPPLEMENT 1 JULY 2014 THE CLINICAL JOURNAL OF THE SOCIETY FOR …